Findings demonstrate immunogenicity and safety of lipid nanoparticle mRNA vaccine against bovine papillomavirus in livestock, suggesting it may reduce papillomas and sarcoids.
Description Bovine papillomavirus (BPV) causes papilloma in cattle and sarcoid in equine resulting in significant health impacts in livestock. Up to date, no commercial vaccine is available against the pathogen. In recent years, the advancement of mRNA vaccine technology offering a faster, more flexible, and more effective solution has paved the way for novel approaches to disease prevention and control. This study focuses on the development of a mRNA BPV vaccine and explores its potential applications for preventing papillomas and equine sarcoids. The mRNA of BPV L1 sequences of BPV1 and BPV2 were synthesized and successfully encapsulated in lipid nanoparticle (LNP). The LNP-formulated BPVL1 mRNA was demonstrated to introduce the mRNA in HEK293 cells and express L1 proteins by western blotting. The immunogenicity and safety were evaluated and confirmed in mice. Our results suggest that the LNP-BPV L1 mRNA might be a potential vaccine candidate for controlling and preventing bovine papillomavirus.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: